Table 1.
Main characteristics of 31 included studies.
| Studies | Study design | N | Response/event (n) | cGVHD incidence (%) | Overall survival rate | median follow-up (months) | |||
|---|---|---|---|---|---|---|---|---|---|
| ORR | ORR at 1 month | CR | CR at 1 month | ||||||
| Basiliximab-based treatment | |||||||||
| Liu, (13) | retrospective | 230 | 151 | 151 | 140 | 140 | 44.80 | 0.617 | 41.8 |
| Tang, (14) | retrospective | 100 | 85 | 85 | 74 | 74 | 43.75 | 0.762 | 25.3 |
| Tan, (15) | prospective, unrandomized | 65 | 59 | 59 | 49 | 49 | 50.00 | 0.547 | 18.5 |
| Chakupurakal, (8) | prospective, unrandomized | 14 | 13 | NA | 7 | NA | NA | NA | NA |
| Nadeau, (16) | retrospective | 21 | 16 | 16 | 9 | 9 | 71.43 | 0.24 | 34.5 |
| Jaiswal, (17) | prospective, unrandomized | 10 | 7 | 7 | 3 | 3 | 16.67 | NA | 4.2 |
| Wang, (18) | retrospective | 53 | 46 | NA | 37 | NA | 69.39 | 0.514 | 0.2 |
| Schmidt-Hieber, (19) | prospective, unrandomized | 23 | 19 | NA | 4 | NA | 62.50 | NA | 6.1 |
| Massenkeil, (20) | retrospective | 17 | 12 | NA | 9 | NA | 61.54 | NA | 4.1 |
| Daclizumab-based treatment | |||||||||
| Tao, (21) | retrospective | 64 | 53 | 53 | 37 | 37 | 34.38 | 0.729 | 0.1 |
| Rager, (22) | retrospective | 17 | 8 | NA | 4 | NA | NA | NA | 1.5 |
| Rao, (23) | retrospective | 22 | 19 | NA | 12 | NA | 50.00 | NA | 16.2 |
| Miano, (24) | retrospective | 13 | 12 | 12 | 6 | 6 | 66.67 | NA | 14.0 |
| Hui, (25) | retrospective | 12 | 2 | 2 | 1 | 1 | NA | NA | 4.0 |
| Perales, (26) | retrospective | 57 | 31 | 31 | NA | NA | NA | NA | 98.0 |
| Teachey, (27) | retrospective | 11 | 7 | NA | 5 | NA | NA | NA | NA |
| Bordigoni, (28) | prospective, unrandomized | 62 | 56 | 56 | 43 | 43 | 67.80 | NA | 1.5 |
| Wolff, (29) | prospective, unrandomized | 21* | 14 | NA | 8 | NA | 66.67 | NA | 19.5 |
| Srinivansan, (30) | retrospective | 3 | 3 | NA | 3 | NA | 100.00 | NA | 4.0 |
| Willenbacher, (31) | prospective, unrandomized | 12 | 8 | 8 | 1 | 1 | NA | NA | 15.3 |
| Preziprka, (32) | prospective, unrandomized | 43 | 22 | 22 | 16 | 16 | NA | 0.4 | 2.6 |
| Inolimomab-based treatment | |||||||||
| Girerd, (34) | prospective, randomized | 49 | NA | NA | NA | NA | NA | 0.469 | 58.4 |
| Garcia-Cadenas, (35) | retrospective | 98 | 38 | 38 | NA | NA | NA | 0.454 | 19.4 |
| van Groningen, (36) | prospective, unrandomized | 21 | 10 | 10 | 6 | 6 | NA | 0.1 | 1.8 |
| Girerd, (37) | retrospective | 33 | 30 | 30 | 24 | 24 | 63.33 | 0.79 | NA |
| Garcia-Cadenas, (35) | retrospective | 92 | 39 | 39 | 13 | 13 | NA | 0.22 | 60.0 |
| Xhaard, (38) | retrospective | 20 | 7 | NA | NA | NA | NA | 0.3 | 74.0 |
| Pinana, (39) | retrospective | 40 | 20 | 20 | 8 | 8 | 78.26 | 0.3 | 1.9 |
| Bay, (40) | retrospective | 85 | 54 | NA | 25 | NA | NA | 0.26 | 20.0 |
| Denileukin diftitox treatment | |||||||||
| Shaughnessy, (10) | prospective, unrandomized | 22 | 9 | 9 | 9 | 9 | 60.00 | NA | 4.0 |
| Ho, (41) | prospective, unrandomized | 30 | 17 | 17 | 8 | 8 | NA | NA | 7.2 |
NA, not available; ORR, overall response rate; CR, complete response rate; cGVHD, chronic graft-versus-host disease.
*Only 20 patients were eligible for evaluation because 1 patient died 5 days after treatment due to rapid progression of pre-existing invasive aspergillosis.